Molecular profiling reveals prognostically significant subtypes of canine lymphoma

Veterinary Pathology

Volumn 50, Issue 4, 2013, Pages 693-703

  Frantz, A M ^a   Sarver, A L ^b   Ito, D ^a,b   Phang, T L ^c,d   Karimpour Fard, A ^c,d   Scott, M C ^a   Valli, V E O ^e   Lindblad Toh, K ^f,g   Burgess, K E ^h   Husbands, B D ^a   Henson, M S ^a,b   Borgatti, A ^a,b   Kisseberth, W C ^i,j   Hunter, L E ^c,d   Breen, M ^k,l   O'Brien, T D ^a,b,m   Modiano, Jaime F ^a,b,m  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e VDX VETERINARY DIAGNOSTICS   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g UPPSALA UNIVERSITY   (Sweden)

^h TUFTS UNIVERSITY   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k NORTH CAROLINA STATE UNIVERSITY   (United States)

^l UNIVERSITY OF NORTH CAROLINA   (United States)

^m UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

Canine; Gene expression profiling; Lymphoma subclassification; Prognostication

Indexed keywords

RNA; TUMOR MARKER;

ANIMAL; B CELL LYMPHOMA; BIOLOGY; CLASSIFICATION; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DNA MICROARRAY; DOG; DOG DISEASE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; IMMUNOPHENOTYPING; MALE; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; T CELL LYMPHOMA; VETERINARY;

ANIMALS; COHORT STUDIES; COMPUTATIONAL BIOLOGY; DISEASE-FREE SURVIVAL; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84883094328     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985812465325     Document Type: Article

References (32)

1. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106(4):1164-1174.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
3. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans: man and his best friend share more than companionship. Chromosome Res. 2008;16(1):145-154.
4. Fosmire SP, Thomas R, Jubala CM, et al. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. Vet Pathol. 2007;44(4):467-478.
5. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med. 2002;16(6):704-709.
6. Gomez-Abad C, Pisonero H, Blanco-Aparicio C, et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood. 2011;118(20):5517-5527.
7. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18): 4836-4843.
8. Ito D, Endicott MM, Jubala CM, et al. A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma. J Vet Intern Med. 2011;25(4):890-896.
9. Ito D, Frantz AM, Williams C, et al. CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma. 2012;53(7):1390-1398.
10. Jubala CM, Wojcieszyn JW, Valli VEO, et al. CD20 expression in normal canine B cells and in canine non-Hodgkin's lymphoma. Vet Pathol. 2005;42(4):468-476.
11. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
12. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520-13525.
13. Modiano JF, Breen M, Valli VE, et al. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia. 2007;21(1):184-187.
14. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851-1861.
15. Piccaluga PP, Agostinelli C, Tripodo C, et al. Peripheral T-cell lymphoma classification: the matter of cellular derivation. Expert Rev Hematol. 2011;4(4):415-425.
16. Ponce F, Marchal T, Magnol JP, et al. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol. 2010;47(3):414-433.
17. Rassnick KM, McEntee MC, Erb HN, et al. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. J Vet Intern Med. 2007;21(6):1364-1373.
18. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
19. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000:365-386.
20. Scott MC, Sarver AL, Gavin KJ, et al. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone. 2011; 49(3):356-367.
21. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74.
22. Sorenmo K, Overley B, Krick E, et al. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Vet Comp Oncol. 2010;8(3):196-208.
23. Starkey MP, Murphy S. Using lymph node fine needle aspirates for gene expression profiling of canine lymphoma. Vet Comp Oncol. 2010;8(1):56-71.
24. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005; 87:163-208.
25. Tamburini BA, Phang TL, Fosmire SP, et al. Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer. 2010; 10(1):619.
26. Tamburini BA, Trapp S, Phang TL, et al. Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS ONE. 2009;4(5): e5549.
27. Thomas R, Seiser EL, Motsinger-Reif A, et al. Refining tumor-associated aneuploidy through "genomic recoding" of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leuk Lymphoma. 2011;52(7):1321-1335.
28. Valli VE, Jacobs RM, Parodi AL, et al. Classification of Hematopoietic Tumors of Domestic Animals. 2nd ser. Washington, DC: American Registry of Pathology; 2002.
29. Valli VE, San Myint M, Barthel A, et al. Classification of canine malignant lymphomas according to the World Health Organization criteria. Vet Pathol. 2011;48(1):198-211.
30. Valli VE, Vernau W, de Lorimier LP, et al. Canine indolent nodular lymphoma. Vet Pathol. 2006;43(3):241-256.
31. Valli VEO. Veterinary pathologists achieve 80% agreement in application of WHO diagnoses to canine lymphoma. Cancer Ther. 2008;6:221-226.
32. Wilkerson MJ, Dolce K, Koopman T, et al. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules. Vet Immunol Immunopathol. 2005;106(3-4):179-196.